|1.||Zunino, F: 3 articles (12/2001 - 05/2000)|
|2.||Pratesi, G: 3 articles (12/2001 - 05/2000)|
|3.||Ojima, I: 2 articles (03/2005 - 08/2001)|
|4.||Ojima, Iwao: 2 articles (05/2004 - 04/2002)|
|5.||Zucchetti, M: 2 articles (12/2001 - 05/2000)|
|6.||Perego, P: 2 articles (12/2001 - 06/2001)|
|7.||Tortoreto, M: 2 articles (12/2001 - 05/2000)|
|8.||D'Incalci, M: 2 articles (12/2001 - 05/2000)|
|9.||Bombardelli, E: 2 articles (12/2001 - 05/2000)|
|10.||Polizzi, D: 2 articles (06/2001 - 05/2000)|
04/01/2002 - "Bay 59-8862 is orally active with high bioavailability, showing excellent activity against a variety of drug-resistant tumors. "
05/01/2000 - "Three other tumor models (LoVo, IGROV/DDP, and U87) with a variable sensitivity to the drug were used to compare the antitumor effects of i.v. and oral treatment with IDN 5109. "
03/01/2005 - "One of them, "Ortataxel" (SB-T-101131, IDN5109, BAY59-8862), exhibits excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines, as well as human tumor xenografts in mice. "
12/15/2001 - "The study provides evidence of an additional pharmacologic advantage of BAY 59-8862, i.e., the ability to affect the growth of intracranial tumors, probably due to the lack of recognition by the P-glycoprotein-mediated transport systems. "
06/01/2001 - "IDN 5109 was included in this study because of its higher potency and efficacy compared with paclitaxel on both tumor systems. "
08/01/2002 - "In the present study, we investigated the cellular response of androgen-independent prostate carcinoma cell lines to the novel taxane IDN 5109 (BAY 59-8862) and evaluated its antitumor activity. "
08/01/2002 - "These results support a potential therapeutic advantage of IDN 5109 over PTX against hormone-refractory prostate carcinoma."
08/15/2001 - "Human MDA435/LCC6mdr1 and MDA435/LCC6 breast carcinoma cells, which express and do not express Pgp, respectively, were incubated with [3H]IDN-5109 and paclitaxel to determine intracellular drug accumulation. "
05/01/2000 - "A comparative study of antitumor activity of Taxol and IDN 5109 given orally was performed in a human breast carcinoma model, MX-1, which is highly responsive to i.v. treatment with both of the taxanes. "
|3.||Central Nervous System Neoplasms
|4.||Neoplasm Metastasis (Metastasis)
|5.||Brain Neoplasms (Brain Tumor)
|6.||Carrier Proteins (Binding Protein)
|8.||K 76 carboxylic acid
|1.||Heterologous Transplantation (Xenotransplantation)